Type 2 Diabetes
Conditions
Keywords
Type 2 diabetes, Basal insulin, Insulin detemir, Insulin titration algorithm
Brief summary
This study compared the effectiveness and safety of two treatment algorithms for insulin detemir initiation and titration: active titration algorithm (performed by investigator weekly) versus usual titration algorithm (performed by study subjects weekly) in patients with type 2 diabetes poorly controlled by OADs.
Detailed description
This is a 24-week, prospective, open-label, randomized, parallel-group study conducted in approximately 200 patients with type 2 diabetes in the Taiwan. The effectiveness of insulin detemir will be assessed at baseline and at 12 and 24 weeks after initiation of study prescription. The safety will be followed during the 24-week study period. Inclusion criteria: Patients must meet all of the following criteria: 1. Men and women with type 2 diabetes. 2. 20 years of age. 3. Patients who have received stable doses of any OADs for at least 10 weeks prior to the screening visit. 4. Patients with inadequate glycemic control (HbA1C \>=7% and \< 11%). 5. Patients who are willing and able to cooperate with study and give signed informed consent. After enrollment, eligible patients will be randomized in a 1:1 ratio to one of the following titration algorithms: * Active titration algorithm: contact with investigator by telephone weekly. * Usual titration algorithm: contact with investigator only at routine study visit.
Interventions
BEHAVIORALActive titration algorithm
Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\<110mg/dl).
BEHAVIORALUsual titration algorithm
All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG\>=110mg/dL, and by 4 IU/day if the FPG\>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \< 70 mg/dL.
Sponsors
Mackay Memorial Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following criteria: 1. Men and women with type 2 diabetes. 2. 20 years of age. 3. Patients who have received stable doses of any OADs for at least 10 weeks prior to the screening visit. 4. Patients with inadequate glycemic control (HbA1C \>=7% and \< 11%). 5. Patients who are willing and able to cooperate with study and give signed informed consent.
Exclusion criteria
1. Patients with type 1 diabetes. 2. Renal dialysis patients. 3. History of hypoglycemia unawareness. 4. Patients who had received any insulin for more than 2 weeks or who have received insulin treatment within 4 weeks prior to screening visit. 5. Patients who have received any investigational products (drug and device) within 4 weeks prior to screening visit. 6. Patients hypersensitive with insulin detemir or its excipients. 7. Patients who are currently pregnant/lactating,or who are preparing for pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare the change in HbA1c between two study groups at Week 24. | 24 weeks | compare the change in HbA1c between two study groups after 24 weeks treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To compare the change in HbA1C between two study groups at Week 12. | 12 weeks | compare the change in HbA1C between two study groups after 12 of treatment. |
| To compare the proportion of patients achieving HbA1C <7% at Week 24 | 24 weeks | compare the proportion of patients achieving HbA1C \<7% after 24 weeks treatment |
| To compare the changes in fasting plasma glucose (FPG) at Week 12 and 24. | 24 weeks | compare the changes in fasting plasma glucose (FPG) after 12 and 24 treatment. |
| To compare the change in body weight at each visit | 24 weeks | compare the change in body weight at each visit |
| To evaluate the incidence of adverse events. | 24 weeks | evaluate the incidence of adverse events including hypoglycemia and any other adverse event. |
Countries
Taiwan
Outcome results
None listed